<?xml version="1.0" encoding="utf-8" standalone="yes"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>Keytruda Sales on FinanClub</title>
    <link>https://finan.club/tags/keytruda-sales/</link>
    <description>Recent content in Keytruda Sales on FinanClub</description>
    <generator>Hugo -- gohugo.io</generator>
    <language>en-us</language>
    <lastBuildDate>Tue, 08 Aug 2023 07:02:27 +0000</lastBuildDate><atom:link href="https://finan.club/tags/keytruda-sales/index.xml" rel="self" type="application/rss+xml" />
    <item>
      <title> MRK</title>
      <link>https://finan.club/us/mrk/</link>
      <pubDate>Tue, 08 Aug 2023 07:02:27 +0000</pubDate>
      
      <guid>https://finan.club/us/mrk/</guid>
      <description>score:1154
Chances: Merck reported stronger-than-expected Q2 earnings and raised its 2023 guidance. Keytruda cancer-drug sales drove better-than-expected Q2 revenue and a raised full-year sales forecast. Merck&amp;rsquo;s top-selling products, Keytruda and HPV vaccine Gardasil, experienced strong demand. Cleveland Clinic has started enrolling subjects in a treatment arm evaluating Anixa&amp;rsquo;s breast cancer vaccine with Keytruda.</description>
    </item>
    
  </channel>
</rss>
